GTBP — GT Biopharma, Inc.

Is GTBP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

GT Biopharma, Inc. (GTBP) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.28. The rating moved from Neutral to Oversold on August 12, 2026.

See all oversold Healthcare stocks →

AI analysis

GT Biopharma, Inc. is a micro‑cap biotech with an early‑stage clinical profile that offers binary upside tied to trial readouts or partnership activity but also significant downside from potential dilution and clinical/regulatory setbacks. The broader sector environment shows supportive demand for biologics and CDMO services, which could improve partnership prospects, while recent market tone is mildly risk‑on—beneficial to speculative healthcare names. However, limited disclosure in the provided data and typically low liquidity increase execution and information risk. Near‑term performance will be driven by financing clarity, clinical milestones, and any partnership or commercialization updates.

Key factors

  • Early‑stage clinical pipeline with novel immunotherapy approach that can generate binary clinical/regulatory catalysts
  • Sector thematic tailwinds for biologics and CDMO/CRO services that could indirectly support valuation and partnership interest
  • Low current share price and small‑cap profile create potential for volatile, high‑leverage moves on news or financings
  • Limited public filing/disclosure activity in the provided data increases uncertainty around financial runway and milestones
  • Market risk‑on tone for growth/biotech modestly supportive for speculative names in the near term

Risks

  • Material dilution risk from near‑term equity or convertible financings to fund operations
  • Clinical, regulatory or trial readout failures that would sharply reduce upside
  • Very low liquidity and high share‑price volatility, making execution of trades and price discovery difficult
  • Lack of recent transparent financial filings or limited visibility into cash runway and burn
  • Competition from larger immuno‑oncology and biologics players with deeper resources
  • Reimbursement, payer dynamics, and commercial execution challenges if programs reach later‑stage approval

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for GTBP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.